Status:

COMPLETED

Patterned Electrical Neuromuscular Stimulation and Therapeutic Exercise for Osteoarthritis of the Knee: Pilot Study

Lead Sponsor:

RS Medical

Collaborating Sponsors:

Accelerated Care Plus

Research Institute of Health and Science (RIHSE)

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of the study is to investigate the benefits of the Patterned Neuromuscular Electrical Stimulation (PENS) for the treatment of osteoarthritis. The rationale for this investigation is to ass...

Detailed Description

There will be two study conditions; patients will be assigned to PENS treatment or to the control group. Study arm 1 - 15 Patients (may be expanded) will receive stimulation with the following parame...

Eligibility Criteria

Inclusion

  • Patient may have evidence of osteoarthritis (radiographic and/or by patient symptoms report) in more than one joint, however, osteoarthritis of one knee has been the patient's primary complaint and the focus of treatment.
  • Radiographic evidence, within 6 months of enrollment, of osteoarthritis of the knee receiving treatment.
  • Kellgren and Lawrence osteoarthritis classification grade 1, 2 or 3 (i.e., indicative of cartilage still remaining in joint).
  • Average rating of pain associated with osteoarthritis of knee greater than or equal to 4 cm (on a 10 cm visual analog scale).
  • Stiffness in knee(s) lasts less than 30 minutes (to demonstrate that stiffness is not from a more serious condition)
  • Agrees to follow their randomized treatment plan and use the device.
  • At least 18 years old.
  • Signed informed consent.
  • Erythrocyte Sedimentation rate greater than 40 mm/hour (Higher rates may be indicative of RA)
  • Agrees to follow the randomized treatment plan and use of the stimulation device.

Exclusion

  • Hypersensitivity to electrical stimulation.
  • Undergone within 3 months of enrollment, corticosteroid or viscosupplementation (i.e., hyaluronate) injections to the effected knee.
  • If taking medications such as oral steroids, non-steroidal anti-inflammatories, or acetaminophen, patient has been on a stable dose for at least 3 months prior to enrollment. (The criteria should match the prior retrospective data studies.)
  • If taking chondroprotective supplements (e.g., glucosamine and chondroitin sulfate), patient has been on a stable dose for at least 3 months prior of enrollment.
  • Pathologic process at the knee (congenital defect or blunt trauma leading to structural defect such as torn anterior cruciate or meniscus ligaments).
  • Problems due to mechanical/anatomical deformities (i.e., valgus greater than 5 degrees or varus greater than 1.5 degrees)
  • Women who are, or plan to become pregnant during the clinical investigation.
  • Known malignancy or cancer.
  • Morbid obesity (BMI \> 40).
  • Serious or uncontrolled systemic illness (e.g., autoimmune disease, rheumatoid arthritis, diabetes mellitus or renal failure).
  • Implanted devices such as a cardiac pacemaker or defibrillator
  • Concurrent use of another electrical stimulation device for treatment of knee symptoms.
  • Ongoing enrollment, or discontinued enrollment within the last 30 days, in another clinical trial for medical devices or biologic agents.
  • Relationship other than medical (e.g., spouse or employee of investigator) with principal investigator(s) and their staff which may bias patient reports.
  • Relationship with another person enrolled in the clinical investigation.
  • Unable to complete the study per the investigational plan or unable to complete the case report forms.

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2010

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00701506

Start Date

May 1 2008

End Date

November 1 2010

Last Update

December 9 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Osaka General Medical Center

Osaka, Japan